Gentian Diagnostics Posts Strong Q2 Growth

Gentian Diagnostics ASA (DE:6FK) has released an update.

Gentian Diagnostics ASA reports a positive second quarter in 2024 with a 12% increase in sales and 13% organic growth compared to the same period in 2023. The company’s EBITDA also saw significant improvement, doubling from the previous year. Growth was driven by products such as fCAL® turbo, which experienced a 26% sales increase, and Cystatin C, with an 8% growth in the same quarter.

For further insights into DE:6FK stock, check out TipRanks’ Stock Analysis page.